Mankind Pharma Limited has received a credit rating update from CRISIL Ratings Limited. CRISIL has reaffirmed the ratings for three tranches of Non-Convertible Debentures (NCDs), each with an amount of ₹400 crore, ₹2,100 crore, and ₹2,500 crore, maintaining a ‘AA+/Stable’ outlook. Additionally, CRISIL has withdrawn the credit ratings for one NCD issuance of ₹2,500 crore and the Commercial Paper programme of ₹1,500 crore.
CRISIL Reaffirms Key Credit Ratings for Mankind Pharma
Mankind Pharma Limited has announced an update regarding its credit ratings from CRISIL Ratings Limited (CRISIL). In a release dated October 29, 2026, CRISIL has confirmed its reaffirmed credit ratings for significant debt instruments issued by the company. This reaffirmation provides continued assurance on the financial stability and creditworthiness of Mankind Pharma.
Details of Reaffirmed and Withdrawn Ratings
CRISIL has reaffirmed the credit ratings for the following Non-Convertible Debenture (NCD) issuances:
- An NCD issuance of ₹400 crore with a rating of Crisil AA+/Stable, which has been Reaffirmed.
- An NCD issuance of ₹2,100 crore also rated Crisil AA+/Stable, which has been Reaffirmed.
Furthermore, CRISIL has withdrawn the credit ratings for:
- An NCD issuance of ₹2,500 crore, previously rated Crisil AA+/Stable.
- The Commercial Paper programme with an amount of ₹1,500 crore, previously rated Crisil A1+.
The detailed rationale provided by CRISIL for these rating actions is accessible via a provided link on the company’s website and the exchange portals.
Source: BSE
